Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS12010 in moderate-to-severe atopic dermatitis
NCT07344051Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of QLS12010 in atopic dermatitis (AD), sponsored by Qilu Pharmaceutical. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
QLS12010
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07344051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07344051.